IL17A and renal fibrosis: However, in the study of Thorenz et al. [40], IL-17A did not play a decisive role in severe renal ischemia–reperfusion injury, and the use of neutralizing monoclonal antibody could not effectively reduce the inflammation and later renal fibrosis caused by renal IRI.